Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
23 Results for "
follicular lymphoma
" in MedChemExpress (MCE) Product Catalog:
Products (23)
23 Results for "follicular lymphoma" in MCE Product Catalog:
11
11 Publications Verification
Synonyms: 2-Chloro-2′-deoxyadenosine; CldAdo; 2CdA
Target:
Research Areas:
Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active adenosine deaminase inhibitor. Cladribine functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis .
2
2 Cited Publications
ARV-393 is a BCL6 PROTAC degrader. ARV-393 forms a complex with BCL6 and Cereblon, induces BCL6 ubiquitination, and mediates BCL6 degradation via the ubiquitin-proteasome system. ARV-393 enhances CD20 expression, interferon pathway activity and antigen presentation. ARV-393 induces tumor growth inhibition and regression. ARV-393 can be used in research related to non-Hodgkin's lymphoma, high-grade B-cell lymphoma, diffuse large B-cell lymphoma, Burkitt's lymphoma and follicular lymphoma .
1
Target:
Research Areas:
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .
Cat. No.: HY-169179
CAS No.: 2984505-88-4
AK-1690 is a selective PROTAC degrader targeting STAT6 (DC50=1 nM) with a Ki of 6 nM against human STAT6. AK-1690 degrades STAT6 via the interaction of STAT6 with cereblon and a ubiquitin-like process. AK-1690 effectively depletes STAT6 protein in mouse liver and lung tissues, and is applicable to research related to leukemia, Hodgkin's lymphoma, follicular lymphoma, etc. .
Synonyms: CC-99282
Research Areas:
Golcadomide (CC-99282) is a blood-brain barrier-permeable, orally active Cereblon (CRBN) E3 ligase modulator. Golcadomide induces Cereblon to form a closed active conformation, thereby recruiting and triggering the ubiquitin-mediated proteasomal degradation of transcription factors IKZF1, IKZF3, Ikaros and Aiolos. Golcadomide is applicable to research related to relapsed or refractory non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and diffuse large B-cell lymphoma .
Cat. No.: HY-121360
CAS No.: 143545-90-8
Category:
Cat. No.: HY-P99056
CAS No.: 1417318-27-4
Synonyms: PF 05082566
Target:
Research Areas:
Cat. No.: HY-172736
CAS No.: 3005272-36-3
Synonyms: BMS-986458
Toviblideg (BMS-986458) is a highly selective, orally active cereblon-based BCL6 PROTAC degrader and antitumor agent. Toviblideg selectively degrades BCL6 by binding cereblon to the BTB domain of BCL6, thereby regulating the cell cycle, antiproliferative and interferon signaling pathways, and upregulating the expression and distribution of CD20. Toviblideg modulates the phenotype of follicular helper T cells and reduces circulating tumor DNA levels. The combination of Toviblideg with CD20xCD3 bispecific antibody also enhances the efficiency of T cell tumor infiltration and expansion. Toviblideg induces regression of BCL6-positive tumors and prolongs survival, and it is suitable for research related to B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, and relapsed/refractory lymphoma .
Cat. No.: HY-P9959
CAS No.: 635715-01-4
Synonyms: CMC-544; PF-5208773; WAY-207294
Target:
Research Areas:
Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody Inotuzumab (HY-P99264) conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin and G544 bind human CD22 with similar affinities (Kd ≈ 150 pM). Inotuzumab ozogamicin has demonstrated efficacy against CD22 + B-cell non-Hodgkin’s lymphoma. Inotuzumab ozogamicin can be used in the research of acute lymphoblastic leukemia .
Synonyms: TG-1701
Edralbrutinib (TG-1701) is a highly selective, orally available irreversible BTK inhibitor, with an EC50 of 6.70 nM and a Kd of 3 nM against human BTK. Edralbrutinib inhibits downstream signaling of the B cell receptor, induces dephosphorylation of Ikaros Ser442/445, promotes nuclear exclusion of Ikaros, attenuates Ikaros gene signatures, and exerts anti-tumor activity. Edralbrutinib can be used in research related to B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma .
Target:
Research Areas:
DM-01 is a powerful and selective EZH2 inhibitor for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and SNF5/INI-1/SMARCB1 genetically defined solid tumors .
Cat. No.: HY-175342
CAS No.: 2248046-39-9
Synonyms: LOXO-338
Target:
Research Areas:
FCN-338 (LOXO-338) is an orally active and selective Bcl-2 inhibitor with an IC50 of 4.5 nM for Bcl-2/BAK interaction. FCN-338 potently inhibits tumor growth in follicular lymphoma (FL), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) xenograft mice model without significant weight loss. FCN-338 has a broad-spectrum anti-cancer activity, such as FL, CLL/SLL, AML, and ALL .
Cat. No.: HY-178694
CAS No.: 120430-77-5
Target:
Research Areas:
DC-PRC2in-01 is a potent EZH2-EED interaction inhibitor with an IC50 of 4.21 μM and a Kd of 4.56 μM. DC-PRC2in-01 disrupts the EZH2-EED interaction, leading to degradation of PRC2 core proteins and decrease of H3K27me3 levels, inhibition of PRC2-driven lymphoma cell proliferation, and cell cycle arrest. DC-PRC2in-01 can be used for the research of PRC2-related cancers, such as Diffuse Large B-cell Lymphoma (DLBCL) and follicular lymphoma (FL) .
Target:
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
PI3K-IN-36 (compound A68) is a potent PI3K inhibitor. PI3K-IN-36 can be used in research of follicular lymphoma (FL) .
Synonyms: 2-Chloro-2′-deoxyadenosine (Standard); CldAdo (Standard); 2CdA (Standard)
Research Areas:
Cladribine (Standard) is the analytical standard of Cladribine. This product is intended for research and analytical applications. Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active adenosine deaminase inhibitor. Cladribine functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis .
Cat. No.: HY-119289
CAS No.: 219501-57-2
Research Areas:
AMP423 is an oxidation inducer and cell cycle regulator. AMP423 induces necrosis, apoptosis, and reactive oxygen species production. AMP423 induces inhibition of protein synthesis, reduction of thiol levels, and S-phase cell accumulation, and exhibits antitumor activity. AMP423 can be used in research related to multiple myeloma and follicular B-cell lymphoma .
Cat. No.: HY-187629
CAS No.: 2202678-04-2
Research Areas:
HH2853 is an orally active EZH1/EZH2 inhibitor, with an IC50 of 9.26 nM for EZH1 and IC50 values ranging from 2.21 to 3.75 nM for both wild-type and mutant EZH2 . HH2853 simultaneously inhibits the methyltransferase activities of EZH1 and EZH2, blocks the compensatory pathway that arises following EZH2 inhibition, and reduces H3K27me3 levels. HH2853 upregulates the expression of c-Myc and TfR-1 to induce intracellular iron accumulation, and stabilizes GPX4 via HSPA5 to suppress ferroptosis. HH2853 combined with Erastin (HY-15763) synergistically inhibits EZH2 wild-type DLBCL cell proliferation. HH2853 alone shows weak activity against EZH2 wild-type DLBCL and is well tolerated. HH2853 is applicable for research related to diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, epithelioid sarcoma, and follicular lymphoma .
Cat. No.: HY-158813
CAS No.: 2364639-42-7
Target:
Research Areas:
S-Geranylgeranyl-L-glutathione is a P2RY8 inhibitor and intercellular signaling molecule that exists endogenously in human bone marrow interstitial fluid. S-Geranylgeranyl-L-glutathione promotes the internalization of P2RY8 and antagonizes chemokine-induced activation of pAkt. S-Geranylgeranyl-L-glutathione negatively regulates the migration of B cells and T cells to the bone marrow, inhibits chemokine-mediated migration of germinal center B cells and follicular helper T cells, participates in lymphocyte guidance regulation, and modulates the germinal center response process. S-Geranylgeranyl-L-glutathione can be used in research related to diffuse large B-cell lymphoma and Burkitt lymphoma .
Cat. No.: HY-P992178
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
